More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$11.76B
EPS
-0.4
P/E ratio
--
Price to sales
2.28
Dividend yield
--
Beta
1.705119
Previous close
$22.55
Today's open
$22.83
Day's range
$22.80 - $23.79
52 week range
$19.40 - $27.98
show more
CEO
Jeffrey N. Simmons
Employees
9450
Headquarters
INDIANAPOLIS, IN
Exchange
New York Stock Exchange
Shares outstanding
499621830
Issue type
Common Stock
Healthcare
Pharmaceuticals
What Growing Up on a Farm Taught Elanco's CEO
One of Jeff Simmons' pivotal leadership lessons came when he was 7 years old. Now CEO of Elanco Animal Health, Simmons said his family's upstate New York grape farm had been devastated by a hailstorm. It was the first time he saw his father cry.
WSJ • Oct 8, 2026

Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground
Elanco Animal Health NYSE: ELAN President and CEO Jeff Simmons outlined the company's growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London.
MarketBeat • Sep 26, 2026

Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • Sep 22, 2026

Elanco to Participate in BofA Securities Global Healthcare Conference 2026
INDIANAPOLIS, Sept. 17, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026.
PRNewsWire • Sep 17, 2026

Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 15, 2026

Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care
Innovation that protects against these pests is driving stronger Elanco base business and overall share gains. Elanco confirms U.S. Pet Health is on track to expectations of high-single digit to low double-digit growth in the second half of 2026.
PRNewsWire • Sep 15, 2026

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement
INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026.
PRNewsWire • Sep 11, 2026

Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
INDIANAPOLIS, Sept. 10, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.
PRNewsWire • Sep 10, 2026

Elanco Director Purchases 40,000 Shares for $936,000
The purchase was valued at $936,000. This investment increased the insider's direct equity position by 27%.
The Motley Fool • Sep 4, 2026

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space.
PRNewsWire • Aug 26, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Elanco Animal Health Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.